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Abstract. The Receptor for Advanced GlycationEndproducts (RAGE) has been suggested to play 
an important role in melanoma. Animal studies with anti-RAGE antibodies have shown that RAGE 
blockade leads to reduced melanoma tumor growth and metastasis formation. RAGE is a multiligand 
receptor and among its ligands are the Ca-binding S100 proteins. Certain S100 proteins are dif-
ferentially expressed in melanoma. For example, S100B is currently used as a reliable prognostic 
biomarker in patients with malignant melanoma. We have surveyed 40 human melanoma tumor 
samples for the transcription of RAGE and five of its known S100 protein ligands. Compared to 
normal skin tissue, we found highly significant (p < 0.0001) over-expression of S100B and under-
expression of S100A2, whereas no significant difference in transcription of S100A6 and S100A10 
was observed. RAGE showed slightly increased transcription in stage IV. Between individual tumor 
samples tremendous differences in transcription of the S100 proteins were observed, whereas RAGE 
expression showed relatively little variance. We also analyzed three well-characterized melanoma 
cell lines for S100 and RAGE expression. The S100 protein transcription profile showed clear differ-
ences between cultured melanoma cells and melanoma tumor tissue. Detailed profiling of S100 and 
RAGE transcription in melanoma tumors in combination with imunohisto-chemical and clinical 
data may lead to improved molecular diagnostic of melanoma and subsequently may facilitate im-
proved treatment in the future.
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Introduction
Metastatic melanoma is characterized by poor (<20%) five-
year survival rates. Many melanomas respond poorly to 
chemotherapy and aggressively form metastases. A better 
understanding of melanoma tumor biology may allow 
personalized chemotherapeutic treatment strategies. One 
of the most reliable biomarkers for melanoma is S100B. It is 
used as a marker for overall tumor load as well as for tumor 
response and survival prognosis during the therapeutic 
process: high serum levels of S100B predict poor treatment 
outcome (Egberts et al. 2008; Hamberg et al. 2003; Hauschild 
et al. 1999; Heizmann 2004; Schultz et al. 1998; Bolander et 
al. 2008; Oberholzer et al. 2008; Andres et al. 2008).
S100B is a member of the S100 protein family, which 
encompasses 21 members of sequence and structure related 
proteins (Marenholz et al. 2006). S100 proteins are small 
EF-hand calcium binding proteins that possess various in-
tra- and extra-cellular functions, including cell proliferation, 
migration, muscle contraction, dynamics of the cytoskeleton 
and metabolic regulation (Donato 2003; Heizmann 2002). 
Members of the S100 protein family have been demonstrated 
to play important roles in tumor progression and tumorigen-
esis in several cancers, including melanoma, through their 
interaction with a number of intracellular target proteins 
(Emberley et al. 2004; Harpio and Einarsson 2004; Van 
Ginkel et al. 1998; Donato 2003; Zimmer et al. 2003). Ex-
tracellular S100 proteins have been described as signals of 
tissue damage and to function as alarmins (Bianchi 2007; 
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Foell et al. 2007). Recently, extracellular S100 proteins have 
been implicated with cancer through their interaction with 
RAGE (Donato 2003; Heizmann et al. 2007). We are focusing 
in this study on five S100 proteins (S100B, S100A2, S100A4, 
S100A6 and S100A10) that have been associated in cancer 
progression and development. 
S100B is highly expressed in melanocytes and in the brain. 
Intracellular S100B interacts with the p53 tumor suppressor 
(Baudier et al. 1992) and is an active target for anti-cancer 
drug development(Markowitz et al. 2005). 
S100A2 was first described as a tumor-suppressor in 
mammary carcinoma cells (Lee et al. 1992) but recent studies 
have found that it is over-expressed in ovarian and gastric 
cancers, suggesting a more complex role for S100A2 in 
cancer (El-Rifai et al. 2002; Hough et al. 2001). In cultured 
epithelial cells, S100A2 has been shown to inhibit cell motil-
ity, probably through modification of actin polymerization/
depolymerization mechanisms (Nagy et al. 2001).
The gene of S100A4 was first identified in metastatic 
tumor cell lines and is thought to play an important role 
in tumor progression and metastasis (Ambartsumian et al. 
2005; Ambartsumian et al. 2001; Ebralidze et al. 1989). The 
role of S100A4 in melanoma tumor progression is not yet 
clear (Maelandsmo et al. 1997; Nonaka et al. 2008).
S100A6 is mainly expressed in fibroblasts and epithelial 
tissue but can also be found in neurons and smooth muscle 
cells (Kuznicki et al. 1989; Kuznicki et al. 1989). S100A6 
expression is up-regulated in several cancers such as acute 
myeloid leukemia (Calabretta et al. 1985), pancreatic cancer 
(Vimalachandran et al. 2005), neuroblastomas and human 
melanomas (Boni et al. 1997; Shrestha et al. 1998; Weterman 
et al. 1992; Weterman et al. 1993)(Nonaka et al. 2008).
S100A10 was first identified in complex with annexin 
2 (Gerke and Weber 1984; Glenney and Tack 1985) and is 
insensitive to calcium due to crucial mutations in its calcium 
binding domains resulting in a locked active conformation 
(Rety et al. 1999). S100A10 is thought to play an important 
role in the trafficking of plasma membrane proteins (Rescher 
and Gerke 2008). S100A10 has been shown to play a role in 
invasiveness of colorectal cancer cells through the interac-
tion with plasminogen (Zhang et al. 2004). High expression 
of S100A10 has also been shown in anaplastic large cell 
lymphoma (Rust et al. 2005) and in renal cell carcinoma 
(Domoto et al. 2007). Down-regulation of S100A10, both at 
the transcript and at the protein levels has also been observed 
in three melanoma cell lines in culture suggesting a putative 
role of S100A10 in melanoma progression (Petersson et al. 
2009).
S100 proteins have specific and common target proteins: 
the tumor suppressor p53 protein appears to be a common 
intracellular target for S100 proteins. p53 is a transcription 
factor that directs cell cycle arrest and apoptosis under stress 
conditions, probably through its tetramerization (Natan et al. 
2009). S100B, S100A2, S100A4, S100A6 and S100A11 have 
been shown to interact with p53 but in distinct ways that 
could result in different effects of p53 dependent cell-cycle 
regulation (Baudier et al. 1992; Rustandi et al. 2000; Rustandi 
et al. 1998; Mueller et al. 2005; Fernandez-Fernandez et al. 
2008; Fernandez-Fernandez et al. 2005).
The Receptor for Advanced GlycationEndproducts, 
RAGE, has been suggested as a common extracellular recep-
tor for S100 proteins (Donato 2007; Heizmann et al. 2007; 
Leclerc et al. 2008; Schmidt et al. 2000). RAGE itself is im-
portant for tumor development, progression and metastasis 
in several cancers including melanoma (Fuentes et al. 2007; 
Heizmann et al. 2007; Logsdon et al. 2007; Turovskaya et al. 
2008; Sparvero et al. 2009; Abe et al. 2004). RAGE is a cell 
surface receptor of the large immunoglobulin like recep-
tor family and can be activated by structurally unrelated 
ligands that include members of the S100 protein family, 
the advanced glycationendproducts (AGE), amphoterin, 
and amyloid forming peptides or proteins. In cells, RAGE 
is present in multiple splice- and proteolytically truncated 
isoforms, the most important being soluble RAGE (sRAGE) 
that plays the role of decoy to antagonize ligand induced 
RAGE signaling (Hudson et al. 2008; Hudson et al. 2005; 
Ramasamy et al. 2009).
Melanomas express RAGE and S100 proteins and the 
stimulation of RAGE by S100 proteins may be a critical 
factor for tumor development, progression and metastasis. 
The spliceisoforms of RAGE might also play an important 
role in melanoma. In order to explore this hypothesis we 
have undertaken a quantitative analysis of mRNA transcript 
levels of S100 proteins (S100B, S100A2, S100A4, S100A6 
and S100A10) and of RAGE (full-length and sRAGE) of 
tissue samples of advanced melanoma (stage III and IV). We 
have also analyzed S100 and RAGE transcription levels in 
three cultured melanoma cell lines to complement the data 
obtained from the melanoma tumor samples.
Materials and methods
Quantitative PCR
A human melanoma tissue cDNA array (TissueScan 
MERT501) was purchased from OriGene (Rockville, MD) 
and consisted of normalized cDNA (against β-actin) from 
three non-tumor skin samples, 21 stage III malignant 
melanoma tumor samples and 19 stage IV malignant 
melanoma tumor samples. The age and gender distribution 
of tumor samples was as followed: stage III, 11 females and 
10 males ranging from age 34 to 81 (median 56); stage IV, 
5 females and 14 males ranging from age 42 to 81 (median 
56). The average tumor content was 82 % (Supplemental 
Table 1). The cDNA of the non-tumor and tumor samples 
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Supplemental Table 1. Description of the melanoma tumor tissue cDNA array: Metastatic melanomas can be classified as stages III to 
IV depending of the spreading of the tumor cells. In stage III, the melanoma has spread to 1 to 3 lymph nodes near the primary tumors. 
In IIIA, the melanoma is not ulcerated and has not spread to other parts of the body. In stages IIIB and C, the melanoma has not spread 
to other parts of the body, it may or may not be ulcerated and may have spread to nearby small areas of skin or lymphatic channels. Stage 
IV melanomas have spread to other part of the body or to distant lymph nodes.
Sample Gender Age Tissue Diagnosis Stage % Tumor % Necrosis % Other tissue
1 Male 36 Skin Fracture of bone 0 0 0 100
2 Not Sp 69 Skin Skin Carcinoma, Merkel cell 0 0 0 100
3 Male 51 Skin Obesity 0 0 0 100
4 Female 42 Lymph node Malig. melanoma, metastatic III 80 15 5
5 Female 59 Lymph node Malig. melanoma, metastatic III 95 5 0
6 Female 66 Lymph node Malig. melanoma, metastatic III 80 0 20
7 Male 56 Lymph node Malig. melanoma, metastatic III 85 5 10
8 Male 46 Lymph node Malig. melanoma, metastatic III 96 2 2
9 Female 66 Lymph node Malig. melanoma, metastatic III 80 20 0
10 Female 34 Lymph node Malig. melanoma, metastatic III 90 0 10
11 Female 56 Lymph node Malig. melanoma, metastatic III 80 20 0
12 Male 59 Lymph node Malig. melanoma, metastatic III 90 5 5
13 Female 49 Lymph node Malig. melanoma, metastatic III 95 5 0
14 Female 67 Lymph node Malig. melanoma, metastatic IIIA 80 0 20
15 Male 61 Lymph node Malig. melanoma, metastatic IIIB 90 10 0
16 Male 43 Lymph node Malig. melanoma, metastatic IIIB 85 7 8
17 Male 42 Lymph node Malig. melanoma, metastatic IIIB 90 0 10
18 Female 49 Lymph node Malig. melanoma, metastatic IIIB 90 0 10
19 Female 72 Lymph node Malig. melanoma, metastatic IIIB 75 0 25
20 Male 50 Groin Malig. melanoma, metastatic IIIB 60 0 40
21 Male 56 Lymph node Malig. melanoma, recurrent IIIC 95 0 5
22 Male 81 Lymph node Malig. melanoma, metastatic IIIC 90 5 5
23 Male 66 Lymph node Malig. melanoma, metastatic IIIC 70 5 25
24 Female 52 Lymph node Malig. melanoma, metastatic IIIC 55 0 45
25 Male 66 Lymph node Malig. melanoma, metastatic IV 75 5 20
26 Female 42 Lung Malig. melanoma, metastatic IV 75 20 5
27 Female 45 Lymph node Malig. melanoma, metastatic IV 80 15 5
28 Female 74 Lung Malig. melanoma, metastatic IV 98 0 2
29 Male 54 Lymph node Malig. melanoma, metastatic IV 70 20 10
30 Male 48 Mesentery Malig. melanoma, metastatic IV 95 0 5
31 Male 60 Jejunum Malig. melanoma, metastatic IV 80 0 20
32 Male 58 Lung Malig. melanoma, metastatic IV 80 0 20
33 Male 45 Lung Malig. melanoma, metastatic IV 90 5 5
34 Male 75 Small intest. Malig. melanoma, metastatic IV 80 15 5
35 Male 56 Liver Malig. melanoma, metastatic IV 75 1 24
36 Male 46 Jejunum Malig. melanoma, metastatic IV 90 10 0
37 Male 56 Lung Malig. melanoma, metastatic IV 90 10 0
38 Female 66 Omentum Malig. melanoma, metastatic IV 90 0 10
39 Male 56 Small intest. Malig. melanoma, metastatic IV 90 5 5
40 Male 81 Lymph node Malig. melanoma, metastatic IV 70 0 30
41 Male 56 Lung Malig. melanoma, metastatic IV 60 40 0
42 Male 73 Lung Malig. melanoma, metastatic IV 65 30 5
43 Female 42 Skin Malig. melanoma, metastatic IV 90 5 5
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of the plate were provided already normalized against β-ac-
tin. Description of the tumor samples can be found in the 
Supplemental Table 1. PCR primers were designed with the 
help of PrimerBank (Wang and Seed 2003; Spandidos et al. 
2008). Primers used are summarized in Table 1. Brilliant II 
SYBR Green QPCR master mix was from Stratagene (La 
Jolla CA). Real-time PCR measurements were performed on 
a Stratagene Mx3005p instrument, in duplicate for the tissue 
sample array and in triplicate for the cell samples. At the end 
of each RT-PCR run, the melting curves were obtained. In 
addition, the correct size of the amplicons was controlled by 
agarose gel electrophoresis.
Cell lines and tissue culture
Melanoma cell lines WM-115 (passage P80), WM-266-4 
(P42) and SK-MEL2 (P40) were generously provided by 
Dr. G.B. Fields (University of Texas Health Science Center, 
San Antonio, Texas). Cells were maintained in opti-MeM 
(Invitrogen, Carlsbad, CA) supplemented with 4% FBS 100 
U/ml penicillin, 100 μg/ml streptomycin. Cells at 70-80% 
confluence were used for mRNA preparation using TRIZOL 
reagent (Invitrogen) according to the manufacturer’s instruc-
tions. The mRNA was immediately reverse transcribed into 
cDNA using a reverse transcription kit (Promega, Madison, 
WI). The cDNA was used in quantitative PCR using a stand-
ard protocol. The cDNAs were normalized to β-actin.
Statistical analysis
Statistical analysis was performed on the Ct values using the 
Student t test for 2 groups of unpaired data with unequal 
variance.
Results
RAGE transcription levels in human melanoma.
We have determined the transcription levels of RAGE in 
a panel of 40 human melanoma tumor tissue samples. 33 out 
of 43 tumor samples contained 75% or more tumor tissue 
according to the manufacturer’s documentation (Origene). 
The tumor samples provided were classified as tumor stage 
III, IIIA-C, tumor stage IV, or lesion stage IV. Three samples 
of normal skin tissue stage 0 were also provided and origi-
nated from non-melanoma patients (Supplemental Table 1). 
We measured the transcript levels of full length RAGE (Fig. 
1A) and sRAGE (Fig. 1B) using the isoform specific primer 
pairs (Table 1). Transcript levels were normalized relative 
to healthy skin and data for individual tumor samples are 
shown in Figure 1. Immediately notable are large differences 
between tumor samples. Some tumors showed close to ten-
fold over-expression of RAGE whereas other samples showed 
over five-fold under-expression relative to normal skin. 
We averaged and compared RAGE transcription in stage 
III and stage IV tumors and analyzed them for significant 
differences. We found statistically significant differences (p 
< 0.05) between stage III and stage IV melanoma tumors, 
with stage IV tumors over-expressing RAGE relative to stage 
III (Fig. 1A).
The analysis of the transcription levels of the sRAGEiso-
form (Fig. 1B) also showed great differences between sam-
ples, with up to 22 fold difference between the lowest and 
the highest transcription levels in either stage III or stage 
IV melanoma tumors. 90% of stage III and stage IV tumors 
were significantly (p < 0.05) under-expressed compared to 
non-melanoma tissue sample. The over-expression of full-
length RAGE between stage III and stage IV tumors and the 
under-expression of sRAGE in both stage III and stage IV 
tumors support the hypothesis of a protective role of sRAGE 
against the detrimental effects of RAGE ligands in normal 
conditions. In pathological conditions, such as melanoma, 
reduced sRAGE expression could enhance the amount of free 
ligand available to full-length RAGE,up-regulated, resulting 
in increased RAGE dependent signaling.
S100 transcription levels in melanoma tumors.
We next analyzed the transcription levels of four S100 genes 
in our tumor samples. Tremendous differences in tran-
scription levels for S100B of over 2,000 fold were observed 
between tumor samples (Fig. 1C). On average transcription 
levels for S100B exceeded normal skin by 100 fold in stage III 
and 200 fold in stage IV tumors. We found a strong statistical 
correlation between S100B expression and tumor stage (p < 
0.0001). Higher stage tumors showed higher S100B transcript 
Table 1. Primer pairs used in real-time PCR experiments
Primer 5’-3’ sequence Amplicon
size
RAGE fwd
RAGE rev
TGTGTGGCCACCCATTCCAG
GCCCTCCAGTACTACTCTCG
309
sRAGE fwd
sRAGE rev
AGCCCTCTCCTCAAATCCACT
CTTTATCAAACCCCTCACCTGC
304
S100B fwd
S100B rev
CCGAACTGAAGGAGCTCATC
AGAACTCGTGGCAGGCAGTA
155
S100A2 fwd
S100A2 rev
CACTACCTTCCACAAGTACT
GAAGTCATTGCACATGAC
229
S100A6 fwd
S100A6 rev
GTGGCCATCTTCCACAAGTA
TTCACCTCCTGGTCCTTGTT
285
S100A10 fwd
S100A10 rev
AAAGACCCTCTGGCTGTGG
AATCCTTCTATGGGGGAAGC
247
β-actin fwd
β-actin rev
CATGTACGTTGCTATCCAGGC
CTCCTTAATGTCACGCACGAT
250
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Figure 1. Transcription levels of RAGE (A), sRAGE 
(B), S100B (C), S100A2 (D), S100A4 (E), S100A6 (F), 
S100A10 (G), in melanoma tumor tissue samples rela-
tive to normal skin. Three non-tumor samples (1 to 3) 
and 40 tumor tissue samples (4 to 43) were analyzed by 
real-time PCR using specific primer pairs as described 
in Table 1 and materials and methods section. The 
experiments were performed in duplicate for each set 
of primers.
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levels. Interestingly, five out of 40 melanoma tumor samples 
presented under-expression of S100B of 3.2 and 9.5 fold 
compared to non tumor samples, in agreement with previous 
studies showing the absence of S100B over-expression in 4% 
of all melanoma tumors (Aisner et al. 2005).
We also measured the transcription levels of the tumor 
suppressor S100A2, which we found to be generally in lower 
abundance in tumor samples (Fig. 1D). S100A2 was statisti-
cally significantly down-regulated (p < 0.0001) in both stage 
III and stage IV tumors when compared to normal skin. 
S100A2 was down-regulated on average 40- to 50-fold but 
showed tremendous differences between individual tumors. 
We did not detect up-regulation of S100A2 transcripts in any 
of the tumor samples (Fig. 1D).
S100A4 was found in higher abundance than S100B in 
normal skin (CtS100A4 = 20.8; CtS100B = 27.8) and its tran-
script levels were significantly decreased (p < 0.05) in stage 
IV tumors (Fig. 1E). We also observed a significant (p < 0.05) 
under-expression of S100A4 transcripts in 76% of stage III 
tumors. Again, large differences in transcripts levels (>500 
fold) were observed between melanoma tumors (Fig. 1E).
S100A6 did not show any significant difference in tran-
scription levels between either stage III or stage IV tumors 
and normal skin even so individual tumors show great dif-
ferences in relative expression: S100A6 transcription levels 
varied by more than a factor of 600 fold among stage III 
tumors and by 50 fold among stage IV tumors (Fig. 1F). 
A detailed analysis showed that 43% and 38% stage III 
tumors showed significant (p < 0.05) over-expression and 
under-expression, respectively, of S100A6 transcripts relative 
to non-tumor samples. Similarly 58% stage IV melanoma 
tumors showed significant (p < 0.05) under-expression of 
S100A6 transcripts compared to reference skin. Similar to 
S100A4 (Ct = 20.8), S100A6 (Ct = 22.2) was highly expressed 
in normal skin. Our results support an earlier study where 
33% of melanomas, characterized by dermato-pathologists 
were found to express S100A6 at the protein level (Ribe and 
McNutt 2003).
S100A10 transcription levels in stage III and stage IV 
tumor samples did not show significant differences when 
compared to reference skin (Fig. 1G). Here again large vari-
ations between samples were observed with more than 200 
fold differences between the lowest and the highest transcrip-
tion levels in melanoma tumors. Detailed analysis showed 
that 58% stage IV melanoma tumors showed significant (p 
< 0.05) under-expression of S100A10.
The analysis of tumor samples for transcription of S100 
proteins and RAGE revealed that S100B was generally 
strongly over-expressed and that the transcription level 
increased with the tumor stage. S100A2 on the other side 
was strongly under-expressed compared to normal skin. In 
average, the transcription ratio between S100A2 and S100B 
was approximately 6:1 in normal skin but reached 1:600 in 
stage III and 1:1500 in stage IV melanomas. Also, the ratio 
between full length RAGE and sRAGE changed between 
normal skin and melanoma tumor tissues from 6:1 to 12,1 
for stage III and to 38,1 for stage IV melanomas.
RAGE and S100 transcription in melanoma cell lines
Although our panel of tumor tissue samples contained 
a high percentile of tumor tissue (mean = 82%), they 
also contained non-tumor tissue that could influence the 
evaluation of the transcription levels of the S100 proteins 
and RAGE. Furthermore “tumor tissue” is intrinsically 
heterogeneous due to non-melanoma cells that invade and 
constitute to tumor mass. We therefore decided to evaluate 
the transcription levels of S100B, S100A2, S100A4, S100A6, 
S100A10, RAGE and sRAGE in three well characterized 
melanoma cell lines: WM-115, WM-266 and SK-Mel2. These 
cell lines are free of non-melanocyte derived cell types. WM-
115 and WM-266 originate from the same patient, WM-115 
derives from the primary tumor whereas WM-266 comes 
from a secondary tumor. The transcription levels of RAGE 
and S100 proteins in these cell lines were normalized to the 
transcription level of β-actin in order to be comparable to 
the results from tissue culture arrays. As in the case of tumor 
tissue, we observed large variations in the transcription 
levels of RAGE and the S100 proteins between the three cell 
lines (Fig. 2).
As a general trend gene transcription levels for RAGE 
and the S100s relative to β-actin were always highest in the 
primary tumor cell line WM-115. RAGE was transcribed 
at lower levels than the S100s, by about two to three orders 
of magnitudes and varied by a factor of approximately 2.5 
between the primary (WM-115) and the metastatic cell line 
WM-266 (Fig. 2A). sRAGE was found in ten times lower 
amount than full-length RAGE in all three cell lines. Inter-
estingly, the ratio between RAGE and sRAGE was generally 
constant between the three melanoma cell lines although it 
varied significantly between the normal skin and melanoma 
stage III (p < 0.0001) or stage IV (p < 0.0001) tumor samples 
(Fig. 2A).
S100B was most highly expressed and exceeded RAGE 
transcription levels by more than three orders of magnitude 
(Fig. 2B). Differences between cell lines did not exceed four-
fold. S100A2 transcripts were found at low levels and in the 
same order of magnitude as RAGE transcripts (Fig. 2C). 
Eight fold variation in transcription levels were observed 
between the three cell lines.
The S100B:S100A2 ratios were approximately 625:1, 
2800: 1 and 560:1 for WM-115, WM-226 and Sk-Mel2, 
respectively.
S100A4 was strongly transcribed and showed greater dif-
ferences between cell lines than the other genes. An almost 
20-fold difference between WM-115 and WM-266 and 
a six-fold difference between WM-266 and SK-Mel2 were 
detected (Fig. 2D).
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S100A6 differed from the emerging pattern between the 
cell lines in that WM-115 and SK-Mel2 had approximately 
equal transcription levels (Fig. 2E).
S100A10 transcription level in the three cell lines was 
the closest to the one of S100B and was similar in the three 
cell lines (Fig. 2F).
The increase in the S100B:S100A2 and RAGE:sRAGE 
ratios observed by the comparison of normal skin with 
melanoma tumor tissues were also observed for cultured 
melanoma cells.
Discussion
RAGE has been suggested to be involved in melanoma pro-
gression and development (Abe et al. 2004). Animal studies 
using anti-RAGE antibodies have demonstrated that RAGE 
blockade can reduce melanoma tumor growth and metas-
tasis formation. Among the RAGE ligands are several S100 
proteins including S100B, S100A2 and S100A6 that have also 
been suggested to be potential biomarkers in melanoma: 
S100B is currently used by clinicians as prognostic marker 
Figure 2. Transcription levels of RAGE and sRAGE (A), S100B (B), S100A2 (C), S100A4 (D), S100A6 (E), S100A10 (F), in melanoma 
cell lines WM-115, WM-266, sk-Mel2. The expression levels of the transcripts were normalized against β-actin. The experiments were 
performed in triplicate. The values of the transcript levels were also normalized by an additional factor of 100 for better representation.
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and high serum levels of S100B correlate with poor survival 
rates (Bolander et al. 2008; Oberholzer et al. 2008; Andres 
et al. 2008). The exact role of S100B in melanoma progres-
sion is still unknown. S100A2, generally described as tumor 
suppressor, was found to be strongly expressed in benign 
nevi and absent in metastatic melanoma, suggesting that 
loss of S100A2 expression could play a role in melanoma 
(Maelandsmo et al. 1997). A recent report also showed that 
over-expression of S100A2 could synergize with interferon α 
resulting in growth inhibition of cutaneous melanoma (Foser 
et al. 2006). In uveal melanoma, up-regulation of S100A2 was 
observed following treatment with decibatine and resulted in 
cell death (Gollob and Sciambi 2007). S100A6 gene expres-
sion was also found in melanocytic lesions (Weterman et al. 
1993) and was shown to correlate with melanoma survival 
rate, a higher S100A6 expression rate being less favorable 
(Maelandsmo et al. 1997).
In our present study, we used a panel of cDNA prepared 
from 40 melanoma tissue samples and from three normal 
skin samples. The objective of our study was to evaluate dif-
ferences in transcription levels between individual tumors 
and between tumor stages relative to normal skin.
Our study detected RAGE, sRAGE, S100B, S100A2, 
S100A4, S100A6 and S100A10 transcripts in melanoma 
tumor cDNA. Averaging stage III and stage IV tumor sam-
ples and comparing them to normal skin we found 100 to 
200 fold increased transcript levels for S100B and 50 fold 
lower transcript levels for S100A2. These differences were 
statistically highly significant (p < 0.0001) and in the case of 
S100B differences between stage III and stage IV were also 
significant (p < 0.001). Differences between normal skin 
and melanoma for RAGE, S100A6 and S100A10 were not 
statistically significant on average. However, differences were 
significant for RAGE and S100A4 between tumor stage III 
and IV, for sRAGE between stage III tumors and normal skin 
and for S100A4 between tumors stage IV in comparison to 
normal skin. However, although no significant difference in 
sRAGE transcription levels was observed when comparing 
all stage IV tumors with normal skin, a significant decrease 
in expression level (p < 0.05) was observed for 89% of these 
tumors. Moreover, although no significant difference could 
be observe, on average, in the transcript levels of S100A6 and 
S100A10 between normal skin and melanoma tumors, the 
finding that 58% of stage IV tumors showed significant (p < 
0.05) decrease in transcript levels of S100A10 and that 43% 
of stage III tumors showed a significant (p < 0.05) increase 
in transcript levels of S100A6 supports previous studies 
performed on both cell lines and tumor tissue samples (Pe-
tersson et al. 2009; Ribe and McNutt 2003).
More important than the average values are the differences 
in transcription levels observed between individual tumor 
samples: 500 fold for S100B, S100A4, S100A6, 200 fold for 
S100A10, 100 fold for S100A2. These variations between 
individual tumors are too large to be the result of tumor tis-
sue content in the biopsied sample. We suggest instead that 
these differences are intrinsic properties of the tumor itself 
and that melanoma tumors develop a molecular signature, 
which can differ between tumors.
Molecular signatures in tumors are an emerging concept. 
Cluster classification of melanoma tumors according to the 
expression of several S100 proteins could be useful at several 
levels: it could help to understand the role of these S100 
proteins in the development and progression of the tumor 
and also help in the diagnosis and prognosis of the cancer. 
S100B is already an established biomarker in melanoma. 
S100A2 shows promising properties as well. The presence 
of large variations in RAGE transcription among melanoma 
tumors may also indicate a possible role of RAGE in a subset 
population of melanoma tumors. 
Tumor profiling based on gene transcription levels does 
not necessarily mirror protein levels in the tumor. However, 
transcript levels can be determined with very high spe-
cificity for a given gene and at very low cost in a very fast 
manner. PCR based diagnostic methods are significantly 
faster and more economical when compared to traditional 
immuno-histochemical methods. This is an important 
consideration when it comes to diagnostic and preven-
tive screening efforts offered to an expanded spectrum of 
patients. The integration of the genetic profiling of RAGE 
and S100 transcription in combination with immuno-his-
tological analysis of tumors could result in earlier diagnosis 
and treatment of melanoma in the future (Kashani-Sabet 
et al. 2009; Viros et al. 2008). For example, suspicious skin 
moles are routinely removed by family doctors and send in 
for immuno-histopathological characterization. A routine 
PCR based ratio determination of S100B:S100A2 and 
RAGE:sRAGE may provide an additional and quantitative 
measure for potential malignancy.
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